「D-二聚体」升高的13种解读,别只想到肺栓塞!

2021-12-22 体外诊断联盟 体外诊断联盟

心内科经常要查D-二聚体,那么这个指标到底跟哪些疾病相关呢?

心内科经常要查D-二聚体,那么这个指标到底跟哪些疾病相关呢?

 

D-二聚体的检查出现在很多疾病中,D-二聚体增高提示了与体内各种原因引起的血栓性疾病相关,同时也说明了纤溶活性的增强

 

临床上常见的有弥慢性血管内凝血(DIC)、深静脉血栓(DVT)、肺栓塞(PE)、急性心肌梗塞、脑梗塞、恶性肿瘤、卵巢癌肺癌、败血症、肝病、妊高征孕妇、先兆子痫、烧伤、外科手术、创伤和脓毒血症等均可使D-二聚体升高。

 

但是D-二聚体检测的升高并不能说明血栓形成的原因及位置,必须结合临床和其他检测分析结果

 

 

那么D-二聚体到底跟哪些疾病相关呢?

 

01 D-二聚体和心梗的关系

 

国内于军等在一项临床研究中发现D-二聚体含量在急性心梗(AMI)患者中较正常组明显升高(P<0.01)。使用尿激溶栓后、心梗组48 h后D-二聚体含量均较前下降。

 

RidkerPM等人的一项研究发现:D-二聚体和缺血性心肌病密切相关,后者的发生率随着D-二聚体浓度的升高而增加(P<0.01)。升高的D-二聚体预示着未来有较高的心梗风险,但不是一个独立的预测因子。

 

02 D-二聚体和脑梗的关系

 

Berge等在一项研究中发现:D-二聚体的水平和脑梗的程度线性相关,不管是在入院时还是在出院后,都可以用来判断脑梗患者的预后。FattoriB等发现在单侧的前庭瘫痪中D-二聚体也升高。国内刘强等的研究发现,血浆D-二聚体水平高的患者,再次发作脑梗的几率也相对较高

 

03 D-二聚体在深静脉血栓中的应用

 

D-二聚体在深静脉血栓中总的诊断价值和在PE中的诊断价值类似:阴性的D-二聚体可以基本排除DVT形成的可能;阳性的结果意义不大(特异性不够强,很多疾病可以引起D-二聚体的升高)。D-二聚体在DVT诊断中的敏感性为95%,特异性为40%,阳性预测值为48%,阴性预测值为95%。

 

JackHirsh等认为,阴性的D-二聚体可以排除深静脉血栓的可能性。联合应用静脉超声检查安全有效,能够大大减少有创的顺行静脉造影检查(曾被认为诊断深静脉血栓的金标准);BounameauxH等的研究证实单一的D-二聚体检查就可以排除门诊1/3怀疑为DVT病人,从而大大节约医疗费用和时间

 

04 D-二聚体和胸主夹层的关系

 

ThomasWeber在对有急性胸痛的病人作了一个前瞻性的研究后发现,所有确诊为胸主夹层的病人D-二聚体都明显升高,升高的程度和发病到实验室检查的时间与夹层的大小相关,但和病人的预后没有关系

 

05 D-二聚体和DIC的关系

 

大量的临床实践证明,作为继发性纤溶亢进的标志性物质,D-二聚体在DIC的诊断和病程监测上具有良好的应用价值。DIC是一种复杂的病理生理过程和严重的获得性、全身性血栓-出血综合征。

 

其特点是体内凝血和抗凝机制失衡导致弥漫性小血管内血栓形成和继发性纤溶亢进。在DIC形成早期即有D-二聚体升高,而且随病程的发展,D-二聚体可持续升高达10倍以上。

 

因此,D-二聚体可作为DIC早期诊断和病程监测的主要指标。另外,D-二聚体与纤维蛋白降解产物(FDP)同时测定,可大大提高其诊断效率

 

06 D-二聚体和肺动脉高压的关系

 

D-二聚体检测对于评估原发性肺动脉高压病人有一定作用,有助于确定重症高危患者。

 

Shitrit等报告血浆D-二聚体水平与纽约心脏病学会心功能分级(P=0.01)及肺动脉压(P=0.03)呈正相关,与动脉血氧饱和度(P=0.03)及6分钟行走距离(P=0.04)呈负相关。

 

1年生存率也与血浆D-二聚体水平呈负相关(P=0.004),血浆二聚体水平较高者预后较差。

 

血浆D-二聚体水平与性别、年龄、肺一氧化碳弥散量及心脏指数无相关性

 

07 D-二聚体和溶栓治疗的检测

 

  • D-二聚体可作为血栓性疾病溶栓治疗的特异性监测指标。在溶栓治疗中,D-二聚体含量变化一般有以下特点:
  • 溶栓后D-二聚体含量在短期内明显上升,而后逐渐下降,提示治疗有效;
  • 溶栓后D-二聚体含量持续升高或下降缓慢,提示溶栓药物用量不足;
需要注意的是,不同疾病的溶栓治疗,D-二聚体峰值变化的时间有所不同。在急性心梗、脑梗溶栓后1~6 hD-二聚体达到峰值,24 h降至溶栓治疗前水平;而在DVT溶栓治疗时,D-二聚体峰值常出现在24 h或以后。
对于慢性期DVT患者,溶栓前D-二聚体含量高于正常,而溶栓后D-二聚体含量不升高,或迅速下降至正常范围,说明此时仅有少量新鲜血栓形成,大部分为机化的陈旧血栓,溶栓常不能收到满意效果。另外,溶栓治疗结束后,应定期观察一段时间的D-二聚体的变化以防血栓复发
D-二聚体与其他系统疾病
01 D-二聚体和肝脏疾病中检测的关系
在肝脏疾病中,血浆D-二聚体的含量明显增高,且与肝病的严重程度呈正相关。Wilder等测定59例急性和慢性肝病患者血浆D-二聚体,其中48例有不同程度地升高。
晋光荣等发现各型肝炎患者D-二聚体水平明显高于对照组,这可能与抗凝系统受损有关。抗纤溶酶及AT—Ⅲ等由肝脏合成,肝病时其合成减少,造成纤溶亢进,在纤溶酶激活下纤维蛋白和纤维蛋白原降解,其降解产物D-二聚体等明显升高。
因此,D-二聚体的浓度可能可以作为一个判断肝脏受损程度的标志
02 D-二聚体和肾病中检测的关系
国内诸葛洪等对47例儿童肾脏病患者及15例正常健康儿进行血浆D-二聚体和血FDP测定,并对15例肾病患儿在应用抗凝治疗前后作动态检测。
结果不同肾病患儿血D-二聚体值均高于正常组,其中以肾病组升高更为显著(P<0.01);15例肾病患儿动态检测结果表明经过抗凝治疗后血D-二聚体值下降并接近正常。
结果提示:在无临床栓塞表现的儿童肾脏病,测定D-二聚体可间接预测高凝状态存在,并可作抗凝药物治疗的依据和预后估计
03 D-二聚体和系统性红斑狼疮(SLE)关系
国内王福党等的研究发现,活动期SLE患者血浆D-二聚体明显高于稳定期及健康对照组,稳定期D-二聚体明显下降,活动期患者随着病情的好转和稳定,其血浆D-二聚体水平逐渐呈下降趋势。可能活动期患者处于高凝状态和纤溶活化,因而造成D-二聚体水平升高。提示D-二聚体可以作为判断SLE疾病活动性和临床疗效的指标
04 妊娠、先兆子痫
Trafatter报告204例先兆子痫妇女中79例D-二聚体增高,而88例正常孕妇全正常。该指标对妊高征患者高凝状态的诊断、疗效观察及预后判断有重要意义。D-二聚体检测排除妊娠VTE:随着妊娠期的发展,孕妇的D-二聚体值随之逐渐升高,可高至基础值的3~4倍。若妊娠期发生VTE,即可干扰D-二聚体排除VTE的有效性。若D-二聚体结果阴性,仍有排除VTE的价值
05 D-二聚体和新生儿窒息检测关系
国内张海英等在一项研究中发现窒息组脐血D-二聚体值明显高于正常对照组(P<0.01)。而重度窒息组脐血D-二聚体值较轻度窒息组升高更为显著(P<0.01)。
06 D-二聚体和恶性肿瘤的关系
大量的文献表明,肿瘤可以引起患者D-二聚体浓度升高,并且可以作为分期、预后等判断标准。MasatoshiOya等在一项研究中发现,结直肠癌患者的D-二聚体比良性疾病患者的明显要高,术前的D-二聚体与肿瘤的病理结果和分期正相关
术前D-二聚体水平高的患者术后生存期明显要比低的患者短。孔荣等对128例恶性肿瘤患者进行D-二聚体测定。结果发现:急性白血病组、恶性淋巴瘤组、实体瘤组初发组分别较对照组明显增高。有明显差异(P<0.05),缓解期明显低于初发期(P<0.05);恶性淋巴瘤组随分期不同D-二聚体水平不同,实体瘤转移组明显高于未转移组,相比差异有显著性(P<0.01)。
OsamuTaguchi等将全部肺癌的患者按照所有患者D-二聚体的中间值150 mg/ul分成两组,高D-二聚体组的生存率比低D-二聚体组低,并且这种预测因素排除了肿瘤分期、组织类型、肿瘤大小对生存期的影响。推测肿瘤患者中高凝血状态是和组织因子依赖的外原性途径和非组织因子相关的肿瘤促凝作用有关。外原性途径被认为是由宿主的单核细胞或者血管内皮细胞激活的。非组织因子相关的肿瘤促凝作用被认为是直接激活因子X。
尿激酶激活纤溶是肿瘤的另一个特征,肿瘤间质细胞分泌的u-PA由肿瘤细胞表面的u-PA受体结合,不仅激活纤溶酶原,造成纤维蛋白降解;而且激活蛋白水解酶,引起肿瘤宿主界面的基质分解,造成肿瘤的转移和侵袭。
 
总之,D-二聚体与多种疾病相关,临床需结合患者具体情况,全面思考,助于判断患者具体病情。

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2100729, encodeId=0f3a2100e292f, content=受益匪浅,谢谢老师, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d67b8139520, createdName=ms2000000484328812, createdTime=Tue Nov 15 19:42:08 CST 2022, time=2022-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092954, encodeId=fc8f209295407, content=d-二聚体升高的倍数和血栓形成之间有相关性吗? , beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200606/779634fdc8944a13a6da20900ae58236/e941130f9cc742b19b7379e5a172b9c0.jpg, createdBy=97c65381808, createdName=Ms🧐🧐🧐🧐🧐🧐, createdTime=Mon Oct 10 21:10:35 CST 2022, time=2022-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950396, encodeId=31801950396ed, content=<a href='/topic/show?id=bfc624041dc' target=_blank style='color:#2F92EE;'>#二聚体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24041, encryptionId=bfc624041dc, topicName=二聚体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Mar 25 15:50:24 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310870, encodeId=252a13108e0d8, content=<a href='/topic/show?id=b15c5628e9' target=_blank style='color:#2F92EE;'>#D-二聚体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5628, encryptionId=b15c5628e9, topicName=D-二聚体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Fri Dec 24 12:50:24 CST 2021, time=2021-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083434, encodeId=1bed1083434cf, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211217/4516b57e09a54b51b9f89aab14b4e53c/7e555f00f9574437ac00736c007c2d13.jpg, createdBy=b6ba6402057, createdName=niu拾柒, createdTime=Thu Dec 23 07:37:43 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083433, encodeId=55ad1083433c7, content=学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbcd5675699, createdName=moyanju2796, createdTime=Thu Dec 23 07:36:49 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083431, encodeId=5a891083431a1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=be335535308, createdName=迷茫的飞翔, createdTime=Thu Dec 23 07:19:50 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083400, encodeId=1a19108340068, content=二聚体还是和所有血栓有关, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636a1401682, createdName=tyl1121, createdTime=Thu Dec 23 02:04:25 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083372, encodeId=db4e10833e2cb, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4f1e3738378, createdName=13583edam47暂无昵称, createdTime=Thu Dec 23 00:06:56 CST 2021, time=2021-12-23, status=1, ipAttribution=)]
    2022-11-15 ms2000000484328812

    受益匪浅,谢谢老师

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2100729, encodeId=0f3a2100e292f, content=受益匪浅,谢谢老师, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d67b8139520, createdName=ms2000000484328812, createdTime=Tue Nov 15 19:42:08 CST 2022, time=2022-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092954, encodeId=fc8f209295407, content=d-二聚体升高的倍数和血栓形成之间有相关性吗? , beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200606/779634fdc8944a13a6da20900ae58236/e941130f9cc742b19b7379e5a172b9c0.jpg, createdBy=97c65381808, createdName=Ms🧐🧐🧐🧐🧐🧐, createdTime=Mon Oct 10 21:10:35 CST 2022, time=2022-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950396, encodeId=31801950396ed, content=<a href='/topic/show?id=bfc624041dc' target=_blank style='color:#2F92EE;'>#二聚体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24041, encryptionId=bfc624041dc, topicName=二聚体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Mar 25 15:50:24 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310870, encodeId=252a13108e0d8, content=<a href='/topic/show?id=b15c5628e9' target=_blank style='color:#2F92EE;'>#D-二聚体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5628, encryptionId=b15c5628e9, topicName=D-二聚体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Fri Dec 24 12:50:24 CST 2021, time=2021-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083434, encodeId=1bed1083434cf, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211217/4516b57e09a54b51b9f89aab14b4e53c/7e555f00f9574437ac00736c007c2d13.jpg, createdBy=b6ba6402057, createdName=niu拾柒, createdTime=Thu Dec 23 07:37:43 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083433, encodeId=55ad1083433c7, content=学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbcd5675699, createdName=moyanju2796, createdTime=Thu Dec 23 07:36:49 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083431, encodeId=5a891083431a1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=be335535308, createdName=迷茫的飞翔, createdTime=Thu Dec 23 07:19:50 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083400, encodeId=1a19108340068, content=二聚体还是和所有血栓有关, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636a1401682, createdName=tyl1121, createdTime=Thu Dec 23 02:04:25 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083372, encodeId=db4e10833e2cb, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4f1e3738378, createdName=13583edam47暂无昵称, createdTime=Thu Dec 23 00:06:56 CST 2021, time=2021-12-23, status=1, ipAttribution=)]
    2022-10-10 Ms🧐🧐🧐🧐🧐🧐

    d-二聚体升高的倍数和血栓形成之间有相关性吗?

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2100729, encodeId=0f3a2100e292f, content=受益匪浅,谢谢老师, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d67b8139520, createdName=ms2000000484328812, createdTime=Tue Nov 15 19:42:08 CST 2022, time=2022-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092954, encodeId=fc8f209295407, content=d-二聚体升高的倍数和血栓形成之间有相关性吗? , beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200606/779634fdc8944a13a6da20900ae58236/e941130f9cc742b19b7379e5a172b9c0.jpg, createdBy=97c65381808, createdName=Ms🧐🧐🧐🧐🧐🧐, createdTime=Mon Oct 10 21:10:35 CST 2022, time=2022-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950396, encodeId=31801950396ed, content=<a href='/topic/show?id=bfc624041dc' target=_blank style='color:#2F92EE;'>#二聚体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24041, encryptionId=bfc624041dc, topicName=二聚体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Mar 25 15:50:24 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310870, encodeId=252a13108e0d8, content=<a href='/topic/show?id=b15c5628e9' target=_blank style='color:#2F92EE;'>#D-二聚体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5628, encryptionId=b15c5628e9, topicName=D-二聚体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Fri Dec 24 12:50:24 CST 2021, time=2021-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083434, encodeId=1bed1083434cf, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211217/4516b57e09a54b51b9f89aab14b4e53c/7e555f00f9574437ac00736c007c2d13.jpg, createdBy=b6ba6402057, createdName=niu拾柒, createdTime=Thu Dec 23 07:37:43 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083433, encodeId=55ad1083433c7, content=学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbcd5675699, createdName=moyanju2796, createdTime=Thu Dec 23 07:36:49 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083431, encodeId=5a891083431a1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=be335535308, createdName=迷茫的飞翔, createdTime=Thu Dec 23 07:19:50 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083400, encodeId=1a19108340068, content=二聚体还是和所有血栓有关, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636a1401682, createdName=tyl1121, createdTime=Thu Dec 23 02:04:25 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083372, encodeId=db4e10833e2cb, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4f1e3738378, createdName=13583edam47暂无昵称, createdTime=Thu Dec 23 00:06:56 CST 2021, time=2021-12-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2100729, encodeId=0f3a2100e292f, content=受益匪浅,谢谢老师, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d67b8139520, createdName=ms2000000484328812, createdTime=Tue Nov 15 19:42:08 CST 2022, time=2022-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092954, encodeId=fc8f209295407, content=d-二聚体升高的倍数和血栓形成之间有相关性吗? , beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200606/779634fdc8944a13a6da20900ae58236/e941130f9cc742b19b7379e5a172b9c0.jpg, createdBy=97c65381808, createdName=Ms🧐🧐🧐🧐🧐🧐, createdTime=Mon Oct 10 21:10:35 CST 2022, time=2022-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950396, encodeId=31801950396ed, content=<a href='/topic/show?id=bfc624041dc' target=_blank style='color:#2F92EE;'>#二聚体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24041, encryptionId=bfc624041dc, topicName=二聚体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Mar 25 15:50:24 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310870, encodeId=252a13108e0d8, content=<a href='/topic/show?id=b15c5628e9' target=_blank style='color:#2F92EE;'>#D-二聚体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5628, encryptionId=b15c5628e9, topicName=D-二聚体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Fri Dec 24 12:50:24 CST 2021, time=2021-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083434, encodeId=1bed1083434cf, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211217/4516b57e09a54b51b9f89aab14b4e53c/7e555f00f9574437ac00736c007c2d13.jpg, createdBy=b6ba6402057, createdName=niu拾柒, createdTime=Thu Dec 23 07:37:43 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083433, encodeId=55ad1083433c7, content=学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbcd5675699, createdName=moyanju2796, createdTime=Thu Dec 23 07:36:49 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083431, encodeId=5a891083431a1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=be335535308, createdName=迷茫的飞翔, createdTime=Thu Dec 23 07:19:50 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083400, encodeId=1a19108340068, content=二聚体还是和所有血栓有关, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636a1401682, createdName=tyl1121, createdTime=Thu Dec 23 02:04:25 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083372, encodeId=db4e10833e2cb, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4f1e3738378, createdName=13583edam47暂无昵称, createdTime=Thu Dec 23 00:06:56 CST 2021, time=2021-12-23, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2100729, encodeId=0f3a2100e292f, content=受益匪浅,谢谢老师, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d67b8139520, createdName=ms2000000484328812, createdTime=Tue Nov 15 19:42:08 CST 2022, time=2022-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092954, encodeId=fc8f209295407, content=d-二聚体升高的倍数和血栓形成之间有相关性吗? , beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200606/779634fdc8944a13a6da20900ae58236/e941130f9cc742b19b7379e5a172b9c0.jpg, createdBy=97c65381808, createdName=Ms🧐🧐🧐🧐🧐🧐, createdTime=Mon Oct 10 21:10:35 CST 2022, time=2022-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950396, encodeId=31801950396ed, content=<a href='/topic/show?id=bfc624041dc' target=_blank style='color:#2F92EE;'>#二聚体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24041, encryptionId=bfc624041dc, topicName=二聚体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Mar 25 15:50:24 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310870, encodeId=252a13108e0d8, content=<a href='/topic/show?id=b15c5628e9' target=_blank style='color:#2F92EE;'>#D-二聚体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5628, encryptionId=b15c5628e9, topicName=D-二聚体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Fri Dec 24 12:50:24 CST 2021, time=2021-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083434, encodeId=1bed1083434cf, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211217/4516b57e09a54b51b9f89aab14b4e53c/7e555f00f9574437ac00736c007c2d13.jpg, createdBy=b6ba6402057, createdName=niu拾柒, createdTime=Thu Dec 23 07:37:43 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083433, encodeId=55ad1083433c7, content=学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbcd5675699, createdName=moyanju2796, createdTime=Thu Dec 23 07:36:49 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083431, encodeId=5a891083431a1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=be335535308, createdName=迷茫的飞翔, createdTime=Thu Dec 23 07:19:50 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083400, encodeId=1a19108340068, content=二聚体还是和所有血栓有关, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636a1401682, createdName=tyl1121, createdTime=Thu Dec 23 02:04:25 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083372, encodeId=db4e10833e2cb, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4f1e3738378, createdName=13583edam47暂无昵称, createdTime=Thu Dec 23 00:06:56 CST 2021, time=2021-12-23, status=1, ipAttribution=)]
    2021-12-23 niu拾柒

    学习了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2100729, encodeId=0f3a2100e292f, content=受益匪浅,谢谢老师, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d67b8139520, createdName=ms2000000484328812, createdTime=Tue Nov 15 19:42:08 CST 2022, time=2022-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092954, encodeId=fc8f209295407, content=d-二聚体升高的倍数和血栓形成之间有相关性吗? , beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200606/779634fdc8944a13a6da20900ae58236/e941130f9cc742b19b7379e5a172b9c0.jpg, createdBy=97c65381808, createdName=Ms🧐🧐🧐🧐🧐🧐, createdTime=Mon Oct 10 21:10:35 CST 2022, time=2022-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950396, encodeId=31801950396ed, content=<a href='/topic/show?id=bfc624041dc' target=_blank style='color:#2F92EE;'>#二聚体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24041, encryptionId=bfc624041dc, topicName=二聚体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Mar 25 15:50:24 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310870, encodeId=252a13108e0d8, content=<a href='/topic/show?id=b15c5628e9' target=_blank style='color:#2F92EE;'>#D-二聚体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5628, encryptionId=b15c5628e9, topicName=D-二聚体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Fri Dec 24 12:50:24 CST 2021, time=2021-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083434, encodeId=1bed1083434cf, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211217/4516b57e09a54b51b9f89aab14b4e53c/7e555f00f9574437ac00736c007c2d13.jpg, createdBy=b6ba6402057, createdName=niu拾柒, createdTime=Thu Dec 23 07:37:43 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083433, encodeId=55ad1083433c7, content=学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbcd5675699, createdName=moyanju2796, createdTime=Thu Dec 23 07:36:49 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083431, encodeId=5a891083431a1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=be335535308, createdName=迷茫的飞翔, createdTime=Thu Dec 23 07:19:50 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083400, encodeId=1a19108340068, content=二聚体还是和所有血栓有关, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636a1401682, createdName=tyl1121, createdTime=Thu Dec 23 02:04:25 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083372, encodeId=db4e10833e2cb, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4f1e3738378, createdName=13583edam47暂无昵称, createdTime=Thu Dec 23 00:06:56 CST 2021, time=2021-12-23, status=1, ipAttribution=)]
    2021-12-23 moyanju2796

    学习。

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2100729, encodeId=0f3a2100e292f, content=受益匪浅,谢谢老师, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d67b8139520, createdName=ms2000000484328812, createdTime=Tue Nov 15 19:42:08 CST 2022, time=2022-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092954, encodeId=fc8f209295407, content=d-二聚体升高的倍数和血栓形成之间有相关性吗? , beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200606/779634fdc8944a13a6da20900ae58236/e941130f9cc742b19b7379e5a172b9c0.jpg, createdBy=97c65381808, createdName=Ms🧐🧐🧐🧐🧐🧐, createdTime=Mon Oct 10 21:10:35 CST 2022, time=2022-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950396, encodeId=31801950396ed, content=<a href='/topic/show?id=bfc624041dc' target=_blank style='color:#2F92EE;'>#二聚体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24041, encryptionId=bfc624041dc, topicName=二聚体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Mar 25 15:50:24 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310870, encodeId=252a13108e0d8, content=<a href='/topic/show?id=b15c5628e9' target=_blank style='color:#2F92EE;'>#D-二聚体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5628, encryptionId=b15c5628e9, topicName=D-二聚体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Fri Dec 24 12:50:24 CST 2021, time=2021-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083434, encodeId=1bed1083434cf, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211217/4516b57e09a54b51b9f89aab14b4e53c/7e555f00f9574437ac00736c007c2d13.jpg, createdBy=b6ba6402057, createdName=niu拾柒, createdTime=Thu Dec 23 07:37:43 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083433, encodeId=55ad1083433c7, content=学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbcd5675699, createdName=moyanju2796, createdTime=Thu Dec 23 07:36:49 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083431, encodeId=5a891083431a1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=be335535308, createdName=迷茫的飞翔, createdTime=Thu Dec 23 07:19:50 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083400, encodeId=1a19108340068, content=二聚体还是和所有血栓有关, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636a1401682, createdName=tyl1121, createdTime=Thu Dec 23 02:04:25 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083372, encodeId=db4e10833e2cb, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4f1e3738378, createdName=13583edam47暂无昵称, createdTime=Thu Dec 23 00:06:56 CST 2021, time=2021-12-23, status=1, ipAttribution=)]
    2021-12-23 迷茫的飞翔

    学习了

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2100729, encodeId=0f3a2100e292f, content=受益匪浅,谢谢老师, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d67b8139520, createdName=ms2000000484328812, createdTime=Tue Nov 15 19:42:08 CST 2022, time=2022-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092954, encodeId=fc8f209295407, content=d-二聚体升高的倍数和血栓形成之间有相关性吗? , beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200606/779634fdc8944a13a6da20900ae58236/e941130f9cc742b19b7379e5a172b9c0.jpg, createdBy=97c65381808, createdName=Ms🧐🧐🧐🧐🧐🧐, createdTime=Mon Oct 10 21:10:35 CST 2022, time=2022-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950396, encodeId=31801950396ed, content=<a href='/topic/show?id=bfc624041dc' target=_blank style='color:#2F92EE;'>#二聚体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24041, encryptionId=bfc624041dc, topicName=二聚体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Mar 25 15:50:24 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310870, encodeId=252a13108e0d8, content=<a href='/topic/show?id=b15c5628e9' target=_blank style='color:#2F92EE;'>#D-二聚体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5628, encryptionId=b15c5628e9, topicName=D-二聚体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Fri Dec 24 12:50:24 CST 2021, time=2021-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083434, encodeId=1bed1083434cf, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211217/4516b57e09a54b51b9f89aab14b4e53c/7e555f00f9574437ac00736c007c2d13.jpg, createdBy=b6ba6402057, createdName=niu拾柒, createdTime=Thu Dec 23 07:37:43 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083433, encodeId=55ad1083433c7, content=学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbcd5675699, createdName=moyanju2796, createdTime=Thu Dec 23 07:36:49 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083431, encodeId=5a891083431a1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=be335535308, createdName=迷茫的飞翔, createdTime=Thu Dec 23 07:19:50 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083400, encodeId=1a19108340068, content=二聚体还是和所有血栓有关, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636a1401682, createdName=tyl1121, createdTime=Thu Dec 23 02:04:25 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083372, encodeId=db4e10833e2cb, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4f1e3738378, createdName=13583edam47暂无昵称, createdTime=Thu Dec 23 00:06:56 CST 2021, time=2021-12-23, status=1, ipAttribution=)]
    2021-12-23 tyl1121

    二聚体还是和所有血栓有关

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2100729, encodeId=0f3a2100e292f, content=受益匪浅,谢谢老师, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d67b8139520, createdName=ms2000000484328812, createdTime=Tue Nov 15 19:42:08 CST 2022, time=2022-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092954, encodeId=fc8f209295407, content=d-二聚体升高的倍数和血栓形成之间有相关性吗? , beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200606/779634fdc8944a13a6da20900ae58236/e941130f9cc742b19b7379e5a172b9c0.jpg, createdBy=97c65381808, createdName=Ms🧐🧐🧐🧐🧐🧐, createdTime=Mon Oct 10 21:10:35 CST 2022, time=2022-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950396, encodeId=31801950396ed, content=<a href='/topic/show?id=bfc624041dc' target=_blank style='color:#2F92EE;'>#二聚体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24041, encryptionId=bfc624041dc, topicName=二聚体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Mar 25 15:50:24 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310870, encodeId=252a13108e0d8, content=<a href='/topic/show?id=b15c5628e9' target=_blank style='color:#2F92EE;'>#D-二聚体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5628, encryptionId=b15c5628e9, topicName=D-二聚体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Fri Dec 24 12:50:24 CST 2021, time=2021-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083434, encodeId=1bed1083434cf, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211217/4516b57e09a54b51b9f89aab14b4e53c/7e555f00f9574437ac00736c007c2d13.jpg, createdBy=b6ba6402057, createdName=niu拾柒, createdTime=Thu Dec 23 07:37:43 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083433, encodeId=55ad1083433c7, content=学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbcd5675699, createdName=moyanju2796, createdTime=Thu Dec 23 07:36:49 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083431, encodeId=5a891083431a1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=be335535308, createdName=迷茫的飞翔, createdTime=Thu Dec 23 07:19:50 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083400, encodeId=1a19108340068, content=二聚体还是和所有血栓有关, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636a1401682, createdName=tyl1121, createdTime=Thu Dec 23 02:04:25 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083372, encodeId=db4e10833e2cb, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4f1e3738378, createdName=13583edam47暂无昵称, createdTime=Thu Dec 23 00:06:56 CST 2021, time=2021-12-23, status=1, ipAttribution=)]
    2021-12-23 13583edam47暂无昵称

    学习了

    0

相关资讯

J Thromb Haemost:D-二聚体水平预测Covid‐19患者住院死亡率

入院时D-二聚体大于2.0μg/mL(增加四倍)可以有效预测Covid-19患者的住院死亡率,这表明D-二聚体可能是改善Covid-19患者治疗早期且有用的标志物。

Lancet:新冠肺炎患者临床进程及死亡风险因素研究

高龄、SOFA评分高、高d-二聚体是新冠肺炎患者死亡高风险的潜在危险因素,这有助于临床医生早期发现预后不良的患者

Heart:D-二聚体与急性心肌梗死后心衰发生率和死亡率的关系

D-二聚体与AMI患者住院后HF的发生率和全因死亡率有关。

Stroke:d-二聚体水平可作为来源不明的栓塞性卒中患者复发的预测因子

d-二聚体水平可以作为预测来源不明的卒中患者复发性卒中,尤其是栓塞性缺血性卒中有用的风险评估生物标志物。

JAHA:缺血性卒中或短暂性脑缺血发作患者D-二聚体水平与全因死亡和不良功能结局的关系

基线和90天D-二聚体水平较高和增加与缺血性卒中或短暂性脑缺血发作患者的不良结局相关。

Blood:新冠病毒感染者的出血和血栓栓塞风险及预测标志物

新冠病毒(COVID-19)患者的D-二聚体水平升高。早期报道提示新冠病毒感染患者有较高的静脉血栓栓塞(VTE)和弥散性血管内凝血(DIC)的概率,但无明确数据。